Overview

Adalimumab Trough Concentrations in Crohn's Disease: A Pilot Pharmacokinetic Study

Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Observational pharmacokinetics study of adalimumab in patients with active refractory Crohn's disease who are naïve to TNF antagonist therapy.
Details
Lead Sponsor:
Universitaire Ziekenhuizen Leuven
Treatments:
Adalimumab